{"Title": ["How Retail Bankruptcies Affect Other Retailers", "IDEXX Laboratories To Present At Stifel Virtual Jaws & Paws Conference; Webcast At 9:45 AM ET", "Have $1,000 to Invest? Billionaires Are Buying These 3 Stocks", "IDEXX Reports Emergency Use Authorization For OPTI SARS-CoV-2 RNA PCR Test Kit", "IDEXX Laboratories Inc (IDXX) Q1 2020 Earnings Call Transcript", "Idexx Laboratories Tops Q1 Estimates Despite COVID-19 Impact", "IDEXX Laboratories Q1 20 Earnings Conference Call At 8:30 AM ET", "IDEXX Labs Withdraws 2020 Guidance", "How Retail Bankruptcies Affect Other Retailers", "IDEXX Launches Coronavirus Test For Pets", "IDXX Crosses Above Average Analyst Target", "Dividend Stocks Worth Considering", "How to Create Stock Baskets", "Nasdaq 100 Movers: EXPE, GILD", "Nasdaq 100 Movers: IDXX, MCHP", "How The Pieces Add Up: SUSA Targets $141", "IDEXX Laboratories Inc Q1 Earnings Climb", "WHO Says There's No Evidence That Pets Can Pass Coronavirus to Humans", "IDEXX Labs Sees No Coronavirus In Pets", "A Promising Healthcare Stock to Watch", "Idexx Laboratories is Now Oversold (IDXX)", "Notable Two Hundred Day Moving Average Cross - IDXX", "Wednesday's ETF with Unusual Volume: IXJ", "The 9 Best 'Purebred' Pet Stocks to Buy", "Is IDEXX Laboratories Stock a Buy?", "IDEXX Laboratories Inc (IDXX) Q4 2019 Earnings Call Transcript", "How Idexx Laboratories Beat Expectations in Q4", "IDEXX Laboratories Q4 19 Earnings Conference Call At 8:30 AM ET", "IDEXX Laboratories Boosts FY20 Outlook - Quick Facts", "IDEXX Laboratories Inc Q4 Profit Rises", "The No-Brainer Industry You Should Be Investing In", "First Week of IDXX March 20th Options Trading", "Validea Warren Buffett Strategy Daily Upgrade Report - 2/4/2020", "Wednesday Sector Leaders: Healthcare, Technology & Communications", "Nasdaq 100 Movers: WBA, IDXX", "Friday Sector Leaders: Consumer Products, Healthcare", "Nasdaq 100 Movers: ILMN, NTES", "S&P 500 Analyst Moves: IDXX", "Why IDEXX Laboratories Stock Dropped 12% in November", "3 Big Stock Charts for Tuesday: Costco, IDEXX Laboratories, and Ulta Beauty", "IDXX Crosses Above Average Analyst Target", "3 Recession-Ready Stocks to Buy Right Now", "We Love Our Pets, and IDEXX Knows It", "Implied SPHB Analyst Target Price: $48", "IDXX Crosses Below Key Moving Average Level", "Tuesday Sector Laggards: Utilities, Healthcare", "IDEXX Laboratories Inc (IDXX) Q3 2019 Earnings Call Transcript", "IDEXX Laboratories Q3 19 Earnings Conference Call At 8:30 AM ET", "You Love Your Dog More Than Humans -- And This Company's Reaping the Benefits", "IDXX Crosses Above Average Analyst Target"], "Elapsed Time": ["MAY 28, 2020", "MAY 27, 2020", "MAY 25, 2020", "MAY 7, 2020", "APR 30, 2020", "APR 30, 2020", "APR 30, 2020", "APR 30, 2020", "MAY 28, 2020", "APR 20, 2020", "APR 10, 2020", "APR 9, 2020", "APR 9, 2020", "MAR 27, 2020", "MAR 23, 2020", "MAR 20, 2020", "APR 30, 2020", "MAR 13, 2020", "MAR 13, 2020", "MAR 6, 2020", "FEB 27, 2020", "FEB 24, 2020", "FEB 19, 2020", "FEB 6, 2020", "MAR 14, 2020", "JAN 31, 2020", "JAN 31, 2020", "JAN 31, 2020", "JAN 31, 2020", "JAN 31, 2020", "JAN 24, 2020", "JAN 22, 2020", "FEB 4, 2020", "JAN 8, 2020", "JAN 8, 2020", "DEC 27, 2019", "DEC 26, 2019", "DEC 12, 2019", "DEC 4, 2019", "NOV 26, 2019", "JAN 16, 2020", "NOV 14, 2019", "NOV 12, 2019", "NOV 12, 2019", "NOV 11, 2019", "NOV 5, 2019", "OCT 31, 2019", "OCT 31, 2019", "NOV 21, 2019", "OCT 21, 2019"], "Published Date": ["May 28, 2020 9:17AM EDT", "May 27, 2020 8:45AM EDT", "May 25, 2020 7:25AM EDT", "May 7, 2020 8:59AM EDT", "Apr 30, 2020 8:00PM EDT", "Apr 30, 2020 12:29PM EDT", "Apr 30, 2020 7:30AM EDT", "Apr 30, 2020 6:49AM EDT", "May 28, 2020 9:17AM EDT", "Apr 20, 2020 8:28AM EDT", "Apr 10, 2020 8:47AM EDT", "Apr 9, 2020 5:36PM EDT", "Apr 9, 2020 11:04AM EDT", "Mar 27, 2020 10:48AM EDT", "Mar 23, 2020 10:30AM EDT", "Mar 20, 2020 8:16AM EDT", "Apr 30, 2020 6:32AM EDT", "Mar 13, 2020 4:51PM EDT", "Mar 13, 2020 7:39AM EDT", "Mar 6, 2020 2:10PM EST", "Feb 27, 2020 4:56PM EST", "Feb 24, 2020 3:11PM EST", "Feb 19, 2020 12:39PM EST", "Feb 6, 2020 4:01AM EST", "Mar 14, 2020 8:08AM EDT", "Jan 31, 2020 4:30PM EST", "Jan 31, 2020 12:00PM EST", "Jan 31, 2020 7:30AM EST", "Jan 31, 2020 6:53AM EST", "Jan 31, 2020 6:39AM EST", "Jan 24, 2020 7:51AM EST", "Jan 22, 2020 11:29AM EST", "Feb 4, 2020 10:00AM EST", "Jan 8, 2020 2:36PM EST", "Jan 8, 2020 10:24AM EST", "Dec 27, 2019 2:56PM EST", "Dec 26, 2019 10:38AM EST", "Dec 12, 2019 11:46AM EST", "Dec 4, 2019 4:26PM EST", "Nov 26, 2019 7:20AM EST", "Jan 16, 2020 9:35AM EST", "Nov 14, 2019 9:03AM EST", "Nov 12, 2019 9:05AM EST", "Nov 12, 2019 8:08AM EST", "Nov 11, 2019 4:28PM EST", "Nov 5, 2019 2:33PM EST", "Oct 31, 2019 3:30PM EDT", "Oct 31, 2019 7:30AM EDT", "Nov 21, 2019 9:00AM EST", "Oct 21, 2019 8:57AM EDT"], "Link": ["https://www.nasdaq.com/articles/how-retail-bankruptcies-affect-other-retailers-2020-05-28", "https://www.nasdaq.com/articles/idexx-laboratories-to-present-at-stifel-virtual-jaws-paws-conference-webcast-at-9%3A45-am-et", "https://www.nasdaq.com/articles/have-%241000-to-invest-billionaires-are-buying-these-3-stocks-2020-05-25", "https://www.nasdaq.com/articles/idexx-reports-emergency-use-authorization-for-opti-sars-cov-2-rna-pcr-test-kit-2020-05-07", "https://www.nasdaq.com/articles/idexx-laboratories-inc-idxx-q1-2020-earnings-call-transcript-2020-05-01", "https://www.nasdaq.com/articles/idexx-laboratories-tops-q1-estimates-despite-covid-19-impact-2020-04-30", "https://www.nasdaq.com/articles/idexx-laboratories-q1-20-earnings-conference-call-at-8%3A30-am-et-2020-04-30", "https://www.nasdaq.com/articles/idexx-labs-withdraws-2020-guidance-2020-04-30", "https://www.nasdaq.com/articles/how-retail-bankruptcies-affect-other-retailers-2020-05-28", "https://www.nasdaq.com/articles/idexx-launches-coronavirus-test-for-pets-2020-04-20", "https://www.nasdaq.com/articles/idxx-crosses-above-average-analyst-target-2020-04-10", "https://www.nasdaq.com/articles/dividend-stocks-worth-considering-2020-04-09", "https://www.nasdaq.com/articles/how-to-create-stock-baskets-2020-04-09", "https://www.nasdaq.com/articles/nasdaq-100-movers%3A-expe-gild-2020-03-27", "https://www.nasdaq.com/articles/nasdaq-100-movers%3A-idxx-mchp-2020-03-23", "https://www.nasdaq.com/articles/how-the-pieces-add-up%3A-susa-targets-%24141-2020-03-20", "https://www.nasdaq.com/articles/idexx-laboratories-inc-q1-earnings-climb-2020-04-30", "https://www.nasdaq.com/articles/who-says-theres-no-evidence-that-pets-can-pass-coronavirus-to-humans-2020-03-13", "https://www.nasdaq.com/articles/idexx-labs-sees-no-coronavirus-in-pets-2020-03-13", "https://www.nasdaq.com/articles/a-promising-healthcare-stock-to-watch-2020-03-06", "https://www.nasdaq.com/articles/idexx-laboratories-is-now-oversold-idxx-2020-02-27", "https://www.nasdaq.com/articles/notable-two-hundred-day-moving-average-cross-idxx-2020-02-24", "https://www.nasdaq.com/articles/wednesdays-etf-with-unusual-volume%3A-ixj-2020-02-19", "https://www.nasdaq.com/articles/the-9-best-purebred-pet-stocks-to-buy-2020-02-06", "https://www.nasdaq.com/articles/is-idexx-laboratories-stock-a-buy-2020-03-14", "https://www.nasdaq.com/articles/idexx-laboratories-inc-idxx-q4-2019-earnings-call-transcript-2020-01-31", "https://www.nasdaq.com/articles/how-idexx-laboratories-beat-expectations-in-q4-2020-01-31", "https://www.nasdaq.com/articles/idexx-laboratories-q4-19-earnings-conference-call-at-8%3A30-am-et-2020-01-31", "https://www.nasdaq.com/articles/idexx-laboratories-boosts-fy20-outlook-quick-facts-2020-01-31", "https://www.nasdaq.com/articles/idexx-laboratories-inc-q4-profit-rises-2020-01-31", "https://www.nasdaq.com/articles/the-no-brainer-industry-you-should-be-investing-in-2020-01-24", "https://www.nasdaq.com/articles/first-week-of-idxx-march-20th-options-trading-2020-01-22", "https://www.nasdaq.com/articles/validea-warren-buffett-strategy-daily-upgrade-report-2-4-2020-2020-02-04", "https://www.nasdaq.com/articles/wednesday-sector-leaders%3A-healthcare-technology-communications-2020-01-08", "https://www.nasdaq.com/articles/nasdaq-100-movers%3A-wba-idxx-2020-01-08", "https://www.nasdaq.com/articles/friday-sector-leaders%3A-consumer-products-healthcare-2019-12-27", "https://www.nasdaq.com/articles/nasdaq-100-movers%3A-ilmn-ntes-2019-12-26", "https://www.nasdaq.com/articles/sp-500-analyst-moves%3A-idxx-2019-12-12", "https://www.nasdaq.com/articles/why-idexx-laboratories-stock-dropped-12-in-november-2019-12-04", "https://www.nasdaq.com/articles/3-big-stock-charts-for-tuesday%3A-costco-idexx-laboratories-and-ulta-beauty-2019-11-26", "https://www.nasdaq.com/articles/idxx-crosses-above-average-analyst-target-2020-01-16", "https://www.nasdaq.com/articles/3-recession-ready-stocks-to-buy-right-now-2019-11-14", "https://www.nasdaq.com/articles/we-love-our-pets-and-idexx-knows-it-2019-11-12", "https://www.nasdaq.com/articles/implied-sphb-analyst-target-price%3A-%2448-2019-11-12", "https://www.nasdaq.com/articles/idxx-crosses-below-key-moving-average-level-2019-11-11", "https://www.nasdaq.com/articles/tuesday-sector-laggards%3A-utilities-healthcare-2019-11-05", "https://www.nasdaq.com/articles/idexx-laboratories-inc-idxx-q3-2019-earnings-call-transcript-2019-10-31", "https://www.nasdaq.com/articles/idexx-laboratories-q3-19-earnings-conference-call-at-8%3A30-am-et-2019-10-31", "https://www.nasdaq.com/articles/you-love-your-dog-more-than-humans-and-this-companys-reaping-the-benefits-2019-11-21", "https://www.nasdaq.com/articles/idxx-crosses-above-average-analyst-target-2019-10-21"], "Content": ["In this episode of Motley Fool Money, Chris Hill chats with Motley Fool analysts Emily Flippen and Ron Gross about the latest news from Wall Street. They talk about the work-from-home culture and the changes it brings. They go through the earning reports of some major retailers and a gaming company, and also discuss the potential delisting of Chinese companies. They share some stocks to keep on your watch list and much more. And TiVo (NASDAQ: TIVO) CEO Dave Shull talks about the future of television.To catch full episodes of all The Motley Fool's free podcasts, check out our podcast center. To get started investing, check out our quick-start guide to investing in stocks. A full transcript follows the video.10 stocks we like better than\u00a0WalmartWhen investing geniuses David and Tom Gardner have an investing tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*David and Tom just revealed what they believe are the\u00a0ten best stocks for investors to buy right now... and Walmart wasn't one of them! That's right -- they think these 10 stocks are even better buys.END", "(RTTNews) - IDEXX Laboratories Inc. (IDXX) will participate in the virtual Stifel Virtual Jaws & Paws Conference.The event is scheduled to begin at 9:45 AM ET on May 27, 2020. To access the live webcast, log on to http://www.idexx.com/investors The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.END", "You could ask 100 different analysts what they think about buying and selling stocks during COVID-19, and you might just get 100 different opinions. That's what's great about tracking hedge funds. You can see where the smart money is being put, and you can see if managers put their money where their mouth is. If you have $1,000 to invest, now could be a great opportunity to start a new position, and billion-dollar hedge fund managers have been scooping up shares of IDEXX Laboratories (NASDAQ: IDXX), Goodyear Tire (NASDAQ: GT) and Starbucks (NASDAQ: SBUX).END", "(RTTNews) - OPTI Medical Systems, Inc., a unit of IDEXX Laboratories, Inc. (IDXX), announced the FDA has granted Emergency Use Authorization for the OPTI SARS-CoV-2 RT-PCR laboratory test kit for the detection of SARS-CoV-2, the virus that causes COVID-19. The test kit provides results in approximately 2-3.5 hours.The OPTI SARS-CoV-2 RT-PCR test kit is based on real-time reverse transcription polymerase chain reaction (RT-PCR), which provides detection of the viral RNA in the sample. It is designed for the detection of SARS-CoV-2 RNA extracted from nasopharyngeal swabs, oropharyngeal swabs, bronchoalveolar lavage and sputum samples. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.END", "END", "Business boomed for Idexx Laboratories (NASDAQ: IDXX) in 2019. But there were plenty of questions for the animal health company in the first quarter of 2020 due to the COVID-19 pandemic. Those questions have now been answered.Idexx Labs announced its first-quarter results before the market opened on Thursday. The company's business is still booming. Here are the highlights from Idexx's Q1 update.END", "(RTTNews) - IDEXX Laboratories Inc. (IDXX) will host a conference call at 8:30 AM ET on April 30, 2020, to discuss Q1 20 earnings results.To access the live webcast, log on to www.idexx.com/investorsTo listen to the call, dial 1-877-336-4441 or 1- 409-207-6985 with access code 1103408. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.END", "(RTTNews) - IDEXX Laboratories Inc. (IDXX) said it has withdrawn 2020 guidance due to the unpredictability of the duration and magnitude of impacts from the COVID-19 pandemic on veterinary service providers.The company said it has enhanced its liquidity and financial flexibility by increasing its credit facility to $1 billion with extended maturity to 2023 and issuing $200 million in 10-year, 2.5% fixed-rate notes.The company noted that it has advanced actions to reduce quarterly operating expenses by approximately $25 million compared to original plan levels. These actions include the temporary reduction of the salaries of chief executive officer by 30%, officers and senior executives by 20% and the majority of other salaried employees by 10%, as well as the suspension of cash compensation for IDEXX's Board of Directors.The savings will mitigate near-term financial impacts from potential revenue declines related to COVID-19 stay-at-home policies and social distancing procedures, the company said in a statement. END", "In this episode of Motley Fool Money, Chris Hill chats with Motley Fool analysts Emily Flippen and Ron Gross about the latest news from Wall Street. They talk about the work-from-home culture and the changes it brings. They go through the earning reports of some major retailers and a gaming company, and also discuss the potential delisting of Chinese companies. They share some stocks to keep on your watch list and much more. And TiVo (NASDAQ: TIVO) CEO Dave Shull talks about the future of television.To catch full episodes of all The Motley Fool's free podcasts, check out our podcast center. To get started investing, check out our quick-start guide to investing in stocks. A full transcript follows the video.10 stocks we like better than\u00a0WalmartWhen investing geniuses David and Tom Gardner have an investing tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*David and Tom just revealed what they believe are the\u00a0ten best stocks for investors to buy right now... and Walmart wasn't one of them! That's right -- they think these 10 stocks are even better buys.END", "(RTTNews) - IDEXX Laboratories said Monday that it has made available the COVID-19 Test for pets. The Test will be available to veterinarians in North America this week and will continue to roll out across most of the world in the coming weeks.The company said the test was necessitated by customer demand and evidence that in rare cases pets living with COVID-19 positive humans can be at risk for SARS-CoV-2 infection.The company said veterinarians usually order IDEXX SARS-CoV-2 (COVID-19) RealPCR Test when Pet is living in a household with a human who has tested positive for the virus; pet is already tested for more common infections that a veterinarian has ruled out; and Pet, particularly cats and ferrets are showing signs consistent with COVID-19. The company does not expect the veterinary test to have an impact on human COVID-19 testing or test availability. END", "\nThere are 4 different analyst targets contributing to that average for Idexx Laboratories, Inc., but the average is just that \u2014 a mathematical average.  There are analysts with lower targets than the average, including one looking for a price of $240.00.  And then on the other side of the spectrum one analyst has a target as high as $276.00.  The standard deviation is $14.84.\n\n\nBut the whole reason to look at the average IDXX price target in the first place is to tap into a \"wisdom of crowds\" effort, putting together the contributions of all the individual minds who contributed to the ultimate number, as opposed to what just one particular expert believes.  And so with IDXX crossing above that average target price of $257.75/share, investors in IDXX have been given a good signal to spend fresh time assessing the company and deciding for themselves: is $257.75 just one stop on the way to an even higher target, or has the valuation gotten stretched to the point where it is time to think about taking some chips off the table?  Below is a table showing the current thinking of the analysts that cover Idexx Laboratories, Inc.:\n\n\nEND", "In this episode of\u00a0Industry Focus: Energy, Nick Sciple and Motley Fool contributor Matt DiLallo bring you some energy headlines from the markets.To catch full episodes of all The Motley Fool's free podcasts, check out our\u00a0podcast center\u00a0. To get started investing, check out our\u00a0quick-start guide to investing in stocks\u00a0. A full transcript follows the video.This video was recorded on April 2, 2020.10 stocks we like better than\u00a0WalmartWhen investing geniuses David and Tom Gardner have an investing tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*David and Tom just revealed what they believe are the\u00a0ten best stocks for investors to buy right now... and Walmart wasn't one of them! That's right -- they think these 10 stocks are even better buys.END", "In this episode of Motley Fool Answers, Alison Southwick is joined by Motley Fool personal finance expert Robert Brokamp and Motley Fool analyst Jason Moser to go through the mailbag to answer listeners' questions. They start with a discussion of the stimulus package. Then they answer listeners' questions about refinancing, why index funds make a great foundation, diversifying your portfolio through multiple accounts, using cash to invest versus paying off a mortgage, and many more interesting questions.They also make some great suggestions on how to spend time if you're locked down at home.To catch full episodes of all The Motley Fool's free podcasts, check out our\u00a0podcast center. To get started investing, check out our\u00a0quick-start guide to investing in stocks. A full transcript follows the video.10 stocks we like better than\u00a0WalmartWhen investing geniuses David and Tom Gardner have an investing tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*END", "In early trading on Friday, shares of Gilead Sciences  topped the list of the day's best performing components of the Nasdaq 100 index, trading up 1.0%.  Year to date, Gilead Sciences registers a 14.8% gain.\n\nAnd the worst performing Nasdaq 100 component thus far on the day is Expedia Group, trading down 8.9%.  Expedia Group is lower by about 45.7% looking at the year to date performance.\n\nTwo other components making moves today are Fox, trading down 8.7%, and Idexx Laboratories trading up 0.9% on the day.\n\n \n\n\n\n\n\n\n\nVIDEO: Nasdaq 100 Movers: EXPE, GILD\nEND", "\nIn early trading on Monday, shares of Microchip Technology topped the list of the day's best performing components of the Nasdaq 100 index, trading up 9.9%.  Year to date, Microchip Technology has lost about 37.4% of its value.\n\nAnd the worst performing Nasdaq 100 component thus far on the day is Idexx Laboratories, trading down 5.5%.  Idexx Laboratories is lower by about 33.7% looking at the year to date performance.\n\nTwo other components making moves today are Sirius XM Holdings, trading down 5.2%, and Micron Technology, trading up 6.2% on the day.\n\n \n\n\n\n\n\n\n\nVIDEO: Nasdaq 100 Movers: IDXX, MCHP\nEND", "Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. \tFor the iShares MSCI USA ESG Select ETF (Symbol: SUSA), we found that the implied analyst target price for the ETF based upon its underlying holdings is $141.05 per unit.\n\n\nWith SUSA trading at a recent price near $103.96 per unit, that means that analysts see 35.68% upside for this ETF looking through to the average analyst targets of the underlying holdings.   Three of SUSA's underlying holdings with notable upside to their analyst target prices are Idexx Laboratories, Inc. (Symbol: IDXX), Marsh & McLennan Companies Inc. (Symbol: MMC), and Quest Diagnostics, Inc. (Symbol: DGX). Although IDXX has traded at a recent price of $193.18/share, the average analyst target is 48.31% higher at $286.50/share. Similarly, MMC has 44.54% upside from the recent share price of $79.03 if the average analyst target price of $114.23/share is reached, and analysts on average are expecting DGX to reach a target price of $111.83/share, which is 41.01% above the recent price of $79.31. Below is a twelve month price history chart comparing the stock performance of IDXX, MMC, and DGX:  \n\n END", "(RTTNews) - IDEXX Laboratories Inc (IDXX) released a profit for its first quarter that advanced from last year.The company's bottom line totaled $111.83 million, or $1.29 per share.  This compares with $102.68 million, or $1.17 per share, in last year's first quarter.Analysts had expected the company to earn $1.20 per share, according to figures compiled by Thomson Reuters.  Analysts' estimates typically exclude special items.The company's revenue for the quarter rose 8.7% to $626.34 million from $576.06 million last year.END", "The World Health Organization (WHO) was previously convinced that cats and dogs couldn't get infected by SARS-CoV-2, the new coronavirus that causes COVID-19. It even had that point listed on its myth-buster web page.But now the agency isn't so sure after a report of a dog that tested positive in Hong Kong after remaining with its owners who had COVID-19. Fortunately for the dog, it didn't have any clinical signs of the disease. But meanwhile, pet health companies including\u00a0Zoetis (NYSE: ZTS) and Heska (NASDAQ: HSKA)\u00a0had been working on developing tests for companion animals that may be affected by COVID-19.While the dog tested positive for the virus, it didn't have a measurable amount antibodies to the virus, but that may be because the virus was cleared so quickly that the dog's immune system didn't have a chance to develop an antibody response.On its website, the WHO noted that \"there is no evidence that a dog, cat or any pet can transmit COVID-19.\"END", "(RTTNews) - IDEXX Laboratories Inc. (IDXX) said that it has seen no positive results in pets to date of SARS-CoV-2, the coronavirus strain responsible for the coronavirus disease 2019 or COVID-19 respiratory outbreak in humans.IDEXX said it evaluated thousands of canine and feline specimens during validation of a new veterinary test system for the COVID-19 virus. The specimens used for test development and validation were obtained from specimens submitted to IDEXX Reference Laboratories for PCR testing.The company noted that the new test results align with the current expert understanding that COVID-19 is primarily transmitted person-to-person and supports the recommendation against testing pets for the COVID-19 virus. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.END", "In this episode of Industry Focus: Wildcard, Motley Fool analysts Jason Moser and Brian Feroldi take a closer look at a new IPO in the healthcare space that aims to fix all the pain points plaguing today's primary healthcare model. We find out about its business strategy and how it aims to address the needs of both consumers and providers. Jason also reviews his Healthcare and Wealthcare basket to check how the stocks are performing.To catch full episodes of all The Motley Fool's free podcasts, check out our\u00a0podcast center. To get started investing, check out our\u00a0quick-start guide to investing in stocks. A full transcript follows the video.10 stocks we like better than 1Life Healthcare, Inc.When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and 1Life Healthcare, Inc. wasn't one of them! That's right -- they think these 10 stocks are even better buys.END", "Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful.  One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.  A stock is considered to be oversold if the RSI reading falls below 30.\n\nIn trading on Thursday, shares of Idexx Laboratories, Inc. (Symbol: IDXX) entered into oversold territory, hitting an RSI reading of 29.3, after changing hands as low as $250 per share.  By comparison, the current RSI reading of the S&P 500 ETF (SPY) is 21.3.  A bullish investor could look at IDXX's 29.3 RSI reading today as a sign that the recent heavy selling is in the process of exhausting itself, and begin to look for entry point opportunities on the buy side.    The chart below shows the one year performance of IDXX shares:\n   \n   END", "In trading on Monday, shares of Idexx Laboratories, Inc. (Symbol: IDXX) crossed below their 200 day moving average of $270.20, changing hands as low as $267.36 per share.  Idexx Laboratories, Inc. shares are currently trading off about 3.1% on the day.  The chart below shows the one year performance of IDXX shares, versus its 200 day moving average:\n\n   END", "The iShares Global Healthcare ETF is seeing unusually high volume in afternoon trading Wednesday, with over 359,000 shares traded versus three month average volume of about 98,000.  Shares of IXJ were up about 0.5% on the day.\n\nComponents of that ETF with the highest volume on Wednesday were Pfizer, trading up about 0.2% with over 6.5 million shares changing hands so far this session, and Merck, off about 0.7% on volume of over 4.9 million shares. Idexx Laboratories is the component faring the best Wednesday, up by about 3.2% on the day, while Mylan is lagging other components of the iShares Global Healthcare ETF, trading lower by about 1.5%. \n\n \n\n\n\n\n\n\n\nVIDEO: Wednesday's ETF with Unusual Volume: IXJ\nThe views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.END", "America's love affair with its pets is creating a booming pet care industry - and, as a result, a small but expanding cluster of pet stocks.Pet care might be bigger than you realize. Edge by Ascential, a market research firm, says that North American spending on pets hit $225 billion in 2018, and is expected to hit $281 billion by 2023 - roughly 5% compound annual growth. Millennials and Gen-Zers are embracing pet ownership in far greater numbers than previous generations; roughly two-thirds of U.S. households own a pet, up from 56% just 30 years ago.Rising demand is fueling a diverse set of pet stocks - companies that provide everything from premium kibble to medications to even pet DNA testing and health insurance.You can get some pet-related exposure among blue chips such as General Mills (GIS), which acquired all-natural pet-food leader Blue Buffalo for $8 billion in 2018. Aon (AON) boasts a top-rated pet insurance business in the form of subsidiary Healthy Paws; Synchrony Financial (SYF) bought a principal rival, Pet's Best, in 2019. However, pet care remains a small portion of their overall business.END", "While they might not represent the most exciting field in the biotech space, animal healthcare companies have been a steady, consistent source of growth in what's often a turbulent market.One company in this area that's worth a look is IDEXX Laboratories (NASDAQ: IDXX). As one of the top providers of animal healthcare diagnostics and veterinary equipment, the company has witnessed a strong 2019. Shares of IDEXX rose by about 40% in 2019, and many expect that this trend will continue going forward.Will 2020 also be a good year for IDEXX Laboratories? Here are a few reasons why it might.END", "END", "Idexx Laboratories\u00a0(NASDAQ: IDXX) delivered a sizzling 40% gain in 2019, handily beating the overall market. The animal healthcare company's companion animal business especially performed well.But Idexx's strong momentum faced a test when the company provided its fiscal 2019 fourth-quarter and full-year update before the market opened on Friday. Here are the highlights from Idexx's\u00a0Q4 results.END", "(RTTNews) - IDEXX Laboratories Inc. (IDXX) will host a conference call at 8:30 AM ET on January 31, 2020, to discuss Q4 19 earnings results.To access the live webcast, log on to www.idexx.com/investorsTo listen to the call, dial 1- 844-767-5679 or 1- 409-207-6967 with access code 176532.For a replay call, dial 1-866-207-1041 or 1- 402-970-0847 with access code 8036553. END", "(RTTNews) - While reporting financial results for the fourth quarter on Friday, pet healthcare company IDEXX Laboratories, Inc. (IDXX) raised its earnings and revenue guidance for the full-year 2020.For fiscal 2020, the company raised its earnings outlook by $0.12 per share to a range of $5.42 to $5.58 per share, a targeted growth of 11 to 14 percent on a reported basis and 13 to 16 percent on a comparable constant currency basis, which excludes a 3 percent growth rate benefit from comparisons to the 2019 CEO transition charges.The company also increased its revenue guidance by $5 million to a range between $2.620 billion and $2.655 billion, reflecting consistent expectations for reported and organic revenue growth of 9 to 10.5 percent.On average, analysts polled by Thomson Reuters expect the company to report earnings of $4.77 per share on revenue growth of 8.5 percent to $2.40 billion for the year. Analysts' estimates typically exclude special items.END", "(RTTNews) - IDEXX Laboratories Inc (IDXX) announced earnings for its fourth quarter that rose from the same period last year.The company's bottom line totaled $90.50 million, or $1.04 per share.  This compares with $85.64 million, or $0.98 per share, in last year's fourth quarter.Analysts had expected the company to earn $0.90 per share, according to figures compiled by Thomson Reuters.  Analysts' estimates typically exclude special items.The company's revenue for the quarter rose 10.2% to $605.45 million from $549.39 million last year.END", "When it comes to guarantees, investing offers virtually none. The closest thing you'll get to a guarantee as an investor is the extremely strong likelihood that the broad-market indexes will increase in value over time. For instance, we've witnessed 37 stocks market corrections of at least 10% (not including rounding) since the beginning of 1950 in the benchmark S&P 500. In each and every occasion, these dips in the market have been completely erased by bull market rallies.Of course, rarely are investors satisfied by simply mirroring the performance of the broader market. Instead, they want to beat it by buying into growth stocks. While picking out individual stocks or specific industries is clearly riskier than simply buying an index fund, I have one oft-overlooked industry that looks to be the closest thing to a no-brainer investment trend that you'll want to be a part of.Ladies and gentlemen, behold the \"paw-tential\" of the pet industry.END", "Investors in Idexx Laboratories, Inc. (Symbol: IDXX) saw new options begin trading this week, for the March 20th expiration.   At Stock Options Channel, our YieldBoost formula has looked up and down the IDXX options chain for the new March 20th contracts and identified one put and one call contract of particular interest.The put contract at the $280.00 strike price has a current bid of $7.70.  If an investor was to sell-to-open that put contract, they are committing to purchase the stock at $280.00, but will also collect the premium, putting the cost basis of the shares at $272.30 (before broker commissions).  To an investor already interested in purchasing shares of IDXX, that could represent an attractive alternative to paying $287.84/share today.\n\nBecause the $280.00 strike represents an approximate 3% discount to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the put contract would expire worthless.  The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 64%.  Stock Options Channel will track those odds over time to see how they change, publishing a chart of those numbers on our website under the contract detail page for this contract.  Should the contract expire worthless, the premium would represent a 2.75% return on the cash commitment, or 17.32% annualized \u2014 at Stock Options Channel we call this the YieldBoost.\n\n\nBelow is a chart showing the trailing twelve month trading history for Idexx Laboratories, Inc., and highlighting in green where the $280.00 strike is located relative to that history:\n\nEND", "The following are today's upgrades for Validea's Patient Investor model based on the published strategy of Warren Buffett. This strategy seeks out firms with long-term, predictable profitability and low debt that trade at reasonable valuations.IDEXX LABORATORIES, INC. (IDXX) is a large-cap growth stock in the Fish/Livestock industry. The rating according to our strategy based on Warren Buffett changed from 72% to 86% based on the firm\u2019s underlying fundamentals and the stock\u2019s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.Company Description: IDEXX Laboratories, Inc. develops, manufactures and distributes products and provides services for the companion animal veterinary, livestock and poultry, dairy and water testing markets. The Company also sells a line of portable electrolytes and blood gas analyzers for the human point-of-care medical diagnostics market. Its segments include diagnostic and information technology-based products and services for the veterinary market, which the Company refers to as the Companion Animal Group; water quality products; diagnostic products and services for livestock and poultry health, which the Company refers to as Livestock, Poultry and Dairy, and Other operating segment, which combines and presents products for the human point-of-care medical diagnostics market with its pharmaceutical product line and its out-licensing arrangements. Its products and services include point-of-care veterinary diagnostic products, comprising instruments, consumables and rapid assay test kits, among others.The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.END", "In afternoon trading on Wednesday, Healthcare stocks are the best performing sector, up 0.8%.  Within that group, Vertex Pharmaceuticals, Inc. (Symbol: VRTX) and Idexx Laboratories, Inc. (Symbol: IDXX) are two of the day's stand-outs, showing a gain of 3.0% and 2.6%, respectively.  Among healthcare ETFs, one ETF following the sector is the Health Care Select Sector SPDR ETF (Symbol: XLV), which is up 0.8% on the day, and up 0.60% year-to-date.  Vertex Pharmaceuticals, Inc., meanwhile, is up 5.32% year-to-date, and Idexx Laboratories, Inc. is up 4.59% year-to-date.  Combined, VRTX and IDXX make up approximately 2.1% of the underlying holdings of XLV.\n\nThe next best performing sector is the Technology & Communications sector, higher by 0.8%.  Among large Technology & Communications stocks, Twitter Inc (Symbol: TWTR) and Synopsys Inc (Symbol: SNPS) are the most notable, showing a gain of 2.5% and 2.5%, respectively.  One ETF closely tracking Technology & Communications stocks is the Technology Select Sector SPDR ETF (XLK), which is up 1.1% in midday trading, and up 2.08% on a year-to-date basis.  Twitter Inc, meanwhile, is up 4.10% year-to-date, and Synopsys Inc is up 5.29% year-to-date.  SNPS makes up approximately 0.3% of the underlying holdings of XLK.\n\nComparing these stocks and ETFs on a trailing twelve month basis, below is a relative stock price performance chart, with each of the symbols shown in a different color as labeled in the legend at the bottom:\n\n\n \n\n\n\n\nEND", "In early trading on Wednesday, shares of Idexx Laboratories (IDXX) topped the list of the day's best performing components of the Nasdaq 100 index, trading up 2.1%. Year to date, Idexx Laboratories registers a 4.0% gain.\n\nAnd the worst performing Nasdaq 100 component thus far on the day is Walgreens Boots Alliance (WBA), trading down 6.7%. Walgreens Boots Alliance is lower by about 6.2% looking at the year to date performance.\n\nTwo other components making moves today are Advanced Micro Devices (AMD), trading down 1.2%, and Vertex Pharmaceuticals (VRTX), trading up 2.1% on the day.\n\n \n\n\n\n\n\n\n\nVIDEO: Nasdaq 100 Movers: WBA, IDXX\nEND", "In afternoon trading on Friday, Consumer Products stocks are the best performing sector, up 0.2%.  Within that group, Conagra Brands Inc (Symbol: CAG) and McCormick & Co Inc (Symbol: MKC) are two large stocks leading the way, showing a gain of 1.6% and 1.4%, respectively.  Among consumer products ETFs, one ETF following the sector is the iShares U.S. Consumer Goods ETF (Symbol: IYK), which is up 0.5% on the day, and up 28.50% year-to-date.  Conagra Brands Inc, meanwhile, is up 64.26% year-to-date, and McCormick & Co Inc is up 24.81% year-to-date.  Combined, CAG and MKC make up approximately 1.6% of the underlying holdings of IYK.\n\nThe next best performing sector is the Healthcare sector, up 0.1%.  Among large Healthcare stocks, Idexx Laboratories, Inc. (Symbol: IDXX) and Laboratory Corporation of America Holdings (Symbol: LH) are the most notable, showing a gain of 0.9% and 0.7%, respectively.  One ETF closely tracking Healthcare stocks is the Health Care Select Sector SPDR ETF (XLV), which is up 0.1% in midday trading, and up 20.80% on a year-to-date basis.  Idexx Laboratories, Inc., meanwhile, is up 41.85% year-to-date, and Laboratory Corporation of America Holdings is up 34.04% year-to-date.  Combined, IDXX and LH make up approximately 1.0% of the underlying holdings of XLV.\n\nComparing these stocks and ETFs on a trailing twelve month basis, below is a relative stock price performance chart, with each of the symbols shown in a different color as labeled in the legend at the bottom:\n\n\n \n\n\n\n\nEND", "In early trading on Thursday, shares of NetEase, topped the list of the day's best performing components of the Nasdaq 100 index, trading up 1.9%. Year to date, NetEase, registers a 30.3% gain.\n\nAnd the worst performing Nasdaq 100 component thus far on the day is Illumina, trading down 1.0%. Illumina is showing a gain of 10.7% looking at the year to date performance.\n\nTwo other components making moves today are Idexx Laboratories, trading down 0.7%, and lululemon athletica, trading up 1.6% on the day.\n\n \n\n\n\n\n\n\n\nVIDEO: Nasdaq 100 Movers: ILMN, NTES \nEND", "The latest tally of analyst opinions from the major brokerage houses shows that among the components of the S&P 500 index, Idexx Laboratories (IDXX) is now the #46 analyst pick, moving up by 1 spot.\n\nThis rank is formed by averaging the analyst opinions for each component from each broker, and then ranking the 500 components by those average opinion values.\n\nLooking at the stock price movement year to date, Idexx Laboratories (IDXX) is showing a gain of 34.6%.\n\n \n\n\n\n\n\n\n\nVIDEO: S&P 500 Analyst Moves: IDXX\nEND", "END", "U.S. stocks set another all-time high on Monday \u2014 and the session feels a bit different. As we\u2019ve noted in this space before, the rally of the last few months has been strangely quiet. Indeed, the 0.78% gain in the S&P 500 was the second-largest daily rally of the last six weeks. The index still has gained nearly 5% over that stretch. This simply has not been a bull market full of irrational exuberance, or anything close. Rather, U.S. stocks have marched steadily higher at a relatively modest pace.With five weeks left in the year, the hope is that Monday\u2019s bigger rally is the first step in  that will drove more gains heading into 2020. If that\u2019s the case, Tuesday\u2019s three big stock charts highlight potential opportunities. None of the three stocks are necessarily cheap, but all have a chance to gain if sentiment strengthens. The one catch might be that these big stock charts show real risk if broad market strength doesn\u2019t materialize.END", "\nThere are 4 different analyst targets contributing to that average for Idexx Laboratories, Inc., but the average is just that \u2014 a mathematical average.  There are analysts with lower targets than the average, including one looking for a price of $260.00.  And then on the other side of the spectrum one analyst has a target as high as $315.00.  The standard deviation is $23.783.\n\n\nBut the whole reason to look at the average IDXX price target in the first place is to tap into a \"wisdom of crowds\" effort, putting together the contributions of all the individual minds who contributed to the ultimate number, as opposed to what just one particular expert believes.  And so with IDXX crossing above that average target price of $286.50/share, investors in IDXX have been given a good signal to spend fresh time assessing the company and deciding for themselves: is $286.50 just one stop on the way to an even higher target, or has the valuation gotten stretched to the point where it is time to think about taking some chips off the table?  Below is a table showing the current thinking of the analysts that cover Idexx Laboratories, Inc.:\n\n\nEND", "It's no secret that global economic growth is slowing right now, and many investors are worried that a downturn is coming. While it's important to note that most economists are not forecasting a recession, investors may still want to position themselves for one, or at least increase the weight of defensive stocks in their portfolios. In this context, here are three investment themes and stocks to prepare for a recessionary scenario.Image source: Getty ImagesEND", "Last week I took my dog Sully to the vet because he wasn't eating (and as anyone who has a Lab can tell you, almost nothing comes between them and their food!). An exam, blood test, and an X-ray later, he was diagnosed with gastritis and given some medicine -- all for the low price of $468. I didn't think twice about the size of the bill because, well... he's a part of our family. I'm not alone in that sentiment: 98% of pet owners feel the same, according to a 2016 survey by The Human Animal Bond Research Institute Foundation in partnership with Cohen Research Group. This close attachment to our pets is precisely what IDEXX Laboratories (NASDAQ: IDXX) is banking on.END", "Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. \tFor the Invesco S&P 500\u2014 High Beta ETF (Symbol: SPHB), we found that the implied analyst target price for the ETF based upon its underlying holdings is $48.26 per unit.\n\n\nWith SPHB trading at a recent price near $43.81 per unit, that means that analysts see 10.15% upside for this ETF looking through to the average analyst targets of the underlying holdings.   Three of SPHB's underlying holdings with notable upside to their analyst target prices are Western Digital Corp (Symbol: WDC), Arista Networks Inc (Symbol: ANET), and Idexx Laboratories, Inc. (Symbol: IDXX). Although WDC has traded at a recent price of $51.99/share, the average analyst target is 17.44% higher at $61.05/share. Similarly, ANET has 14.70% upside from the recent share price of $191.17 if the average analyst target price of $219.26/share is reached, and analysts on average are expecting IDXX to reach a target price of $286.50/share, which is 13.38% above the recent price of $252.68. Below is a twelve month price history chart comparing the stock performance of WDC, ANET, and IDXX:  \n\n END", "In trading on Monday, shares of Idexx Laboratories, Inc. (Symbol: IDXX) crossed below their 200 day moving average of $252.60, changing hands as low as $251.60 per share.  Idexx Laboratories, Inc. shares are currently trading down about 0.8% on the day.  The chart below shows the one year performance of IDXX shares, versus its 200 day moving average:\n\n   END", "Looking at the sectors faring worst as of midday Tuesday, shares of Utilities companies are underperforming other sectors, showing a 0.7% loss.  Within the sector, NRG Energy Inc (Symbol: NRG) and AES Corp. (Symbol: AES) are two large stocks that are lagging, showing a loss of 2.7% and 1.6%, respectively.  Among utilities ETFs, one ETF following the sector is the Utilities Select Sector SPDR ETF (Symbol: XLU), which is down 0.7% on the day, and up 21.37% year-to-date.  NRG Energy Inc, meanwhile, is up 0.56% year-to-date, and AES Corp. is up 22.39% year-to-date.  Combined, NRG and AES make up approximately 2.4% of the underlying holdings of XLU.\n\nThe next worst performing sector is the Healthcare sector, showing a 0.6% loss.  Among large Healthcare stocks, Mylan NV (Symbol: MYL) and Idexx Laboratories, Inc. (Symbol: IDXX) are the most notable, showing a loss of 6.5% and 5.2%, respectively.  One ETF closely tracking Healthcare stocks is the Health Care Select Sector SPDR ETF (XLV), which is down 0.6% in midday trading, and up 9.93% on a year-to-date basis.  Mylan NV, meanwhile, is down 32.65% year-to-date, and Idexx Laboratories, Inc. is up 41.96% year-to-date.  Combined, MYL and IDXX make up approximately 1.0% of the underlying holdings of XLV.\n\nComparing these stocks and ETFs on a trailing twelve month basis, below is a relative stock price performance chart, with each of the symbols shown in a different color as labeled in the legend at the bottom:\n\n\n \n\n\n\n\nEND", "END", "(RTTNews) - IDEXX Laboratories Inc. (IDXX) will host a conference call at 8:30 AM ET on October 31, 2019, to discuss Q3 19 earnings results.To access the live webcast, log on to www.idexx.com/investorsTo listen to the call, dial 1-800-230-1096 or 1-612-332-0335 and reference confirmation code 472946.For a replay call, dial 1-800-475-6701 or 1-320-365-3844 with code 472946. END", "\"Dog is a man's best friend,\" is more than a playful expression, as it turns out.\u00a0According to a survey conducted by Mercure Hotels, a dog-friendly lodging company, more than half (53%) of dog and companion pet owners admit they enjoy the company of their pet more than that of their human best friends.Our love for companion animals shows up in our bank statements too. U.S. pet owners are expected to spend a record $75 billion on their pets this year, including $19 billion on veterinary care alone, according to a recent\u00a0study\u00a0the American Pet Products Association.\u00a0END", "\nThere are 4 different analyst targets contributing to that average for Idexx Laboratories, Inc., but the average is just that \u2014 a mathematical average.  There are analysts with lower targets than the average, including one looking for a price of $260.00.  And then on the other side of the spectrum one analyst has a target as high as $300.00.  The standard deviation is $18.355.\n\n\nBut the whole reason to look at the average IDXX price target in the first place is to tap into a \"wisdom of crowds\" effort, putting together the contributions of all the individual minds who contributed to the ultimate number, as opposed to what just one particular expert believes.  And so with IDXX crossing above that average target price of $282.75/share, investors in IDXX have been given a good signal to spend fresh time assessing the company and deciding for themselves: is $282.75 just one stop on the way to an even higher target, or has the valuation gotten stretched to the point where it is time to think about taking some chips off the table?  Below is a table showing the current thinking of the analysts that cover Idexx Laboratories, Inc.:\n\n\nEND"]}